The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts, The Journal of Cell Biology, vol.108, issue.3, pp.527-538, 1999. ,
DOI : 10.1016/0006-291X(89)91143-1
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proceedings of the National Academy of Sciences, vol.96, issue.7, pp.3540-3545, 1999. ,
DOI : 10.1073/pnas.96.7.3540
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22329
Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis, Biochemical and Biophysical Research Communications, vol.234, issue.1, pp.137-142, 1997. ,
DOI : 10.1006/bbrc.1997.6603
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997. ,
DOI : 10.1016/S0092-8674(00)80209-3
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL, Journal of Biological Chemistry, vol.273, issue.23, pp.14363-14367, 1998. ,
DOI : 10.1074/jbc.273.23.14363
Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, vol.3, issue.6, pp.673-682, 1995. ,
DOI : 10.1016/1074-7613(95)90057-8
Haemophilias A and B, The Lancet, vol.361, issue.9371, pp.1801-1809, 2003. ,
DOI : 10.1016/S0140-6736(03)13405-8
New Concepts in Von Willebrand Disease, Annual Review of Medicine, vol.56, issue.1, pp.173-191, 2005. ,
DOI : 10.1146/annurev.med.56.082103.104713
Platelet Dysfunction and a High Bone Mass Phenotype in a Murine Model of Platelet-Type von Willebrand Disease, The American Journal of Pathology, vol.172, issue.2, pp.430-439, 2008. ,
DOI : 10.2353/ajpath.2008.070417
Hemophilia, low bone mass, and osteopenia/osteoporosis, Transfusion and Apheresis Science, vol.38, issue.1, pp.33-40, 2008. ,
DOI : 10.1016/j.transci.2007.12.003
Osteoporosis in haemophilia ? an underestimated comorbidity?, Haemophilia, vol.292, issue.1, pp.79-84, 2007. ,
DOI : 10.1053/jinf.2002.1109
Crystal Structure of the Wild-type von Willebrand Factor A1-Glycoprotein Ib?? Complex Reveals Conformation Differences with a Complex Bearing von Willebrand Disease Mutations, Journal of Biological Chemistry, vol.279, issue.22, pp.23327-23334, 2004. ,
DOI : 10.1074/jbc.M401659200
Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor, Biochemical and Biophysical Research Communications, vol.339, issue.4, pp.1178-1183, 2006. ,
DOI : 10.1016/j.bbrc.2005.11.126
Crystal Structure of von Willebrand Factor A1 Domain Complexed with Snake Venom, Bitiscetin: INSIGHT INTO GLYCOPROTEIN Ib?? BINDING MECHANISM INDUCED BY SNAKE VENOM PROTEINS, Journal of Biological Chemistry, vol.278, issue.39, pp.37777-37781, 2003. ,
DOI : 10.1074/jbc.M305566200
Structural Basis of von Willebrand Factor Activation by the Snake Toxin Botrocetin, Structure, vol.10, issue.7, pp.943-950, 2002. ,
DOI : 10.1016/S0969-2126(02)00787-6
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor, Journal of Cellular Physiology, vol.156, issue.2, pp.714-723, 2005. ,
DOI : 10.1002/jcp.20354
Characterization of the interaction between von Willebrand factor and osteoprotegerin, Journal of Thrombosis and Haemostasis, vol.98, issue.9, pp.1956-1962, 2007. ,
DOI : 10.1111/j.1538-7836.2007.02681.x
Phosphorylation of Signal Transducer and Activator of Transcription 3, Endocrinology, vol.149, issue.7, pp.3688-3697, 2008. ,
DOI : 10.1210/en.2007-1719
URL : https://hal.archives-ouvertes.fr/inserm-00667501
Basic local alignment search tool, Journal of Molecular Biology, vol.215, issue.3, pp.403-410, 1990. ,
DOI : 10.1016/S0022-2836(05)80360-2
Clustal W and Clustal X version 2.0, Bioinformatics, vol.23, issue.21, pp.2947-2948, 2007. ,
DOI : 10.1093/bioinformatics/btm404
URL : https://hal.archives-ouvertes.fr/hal-00206210
The Jalview Java alignment editor, Bioinformatics, vol.20, issue.3, pp.426-427, 2004. ,
DOI : 10.1093/bioinformatics/btg430
Comparative Protein Modelling by Satisfaction of Spatial Restraints, Journal of Molecular Biology, vol.234, issue.3, pp.779-815, 1993. ,
DOI : 10.1006/jmbi.1993.1626
Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-A Resolution, Journal of Biological Chemistry, vol.277, issue.8, pp.6631-6636, 2002. ,
DOI : 10.1074/jbc.M106525200
VMD: Visual molecular dynamics, Journal of Molecular Graphics, vol.14, issue.1, pp.33-38, 1996. ,
DOI : 10.1016/0263-7855(96)00018-5
Disabling of Receptor Activator of Nuclear Factor-??B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo, Journal of Biological Chemistry, vol.279, issue.9, pp.8269-8277, 2004. ,
DOI : 10.1074/jbc.M309690200
Hemophilic Arthropathy, Archives of Surgery, vol.72, issue.2, pp.247-250, 1956. ,
DOI : 10.1001/archsurg.1956.01270200063011
Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage, Haemophilia, vol.43, issue.1, pp.10-13, 2007. ,
DOI : 10.1111/j.1365-2516.2005.01080.x
Physiopathology of haemophilic arthropathy, Haemophilia, vol.13, issue.3, pp.3-9, 2008. ,
DOI : 10.1002/art.21211
Receptor Activator of Nuclear Factor ??B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease, Endocrine Reviews, vol.29, issue.2, pp.155-192, 2008. ,
DOI : 10.1210/er.2007-0014
Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis, Cellular and Molecular Life Sciences (CMLS), vol.59, issue.9, pp.1569-1576, 2002. ,
DOI : 10.1007/s00018-002-8530-7
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial??calcification, Genes & Development, vol.12, issue.9, pp.1260-1268, 1998. ,
DOI : 10.1101/gad.12.9.1260
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC316769
Does Hemophilia Protect Against Atherosclerosis? A Case-Control Study, Clinical and Applied Thrombosis/Hemostasis, vol.37, issue.3, pp.193-198, 2006. ,
DOI : 10.1177/107602960601200207
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized, British Journal of Haematology, vol.31, issue.2, pp.1109-1113, 1999. ,
DOI : 10.1046/j.1365-2796.1997.130135000.x
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, New England Journal of Medicine, vol.357, issue.6, pp.535-544, 2007. ,
DOI : 10.1056/NEJMoa067659
The TRAIL apoptotic pathway in cancer onset, progression and therapy, Nature Reviews Cancer, vol.3, issue.10, pp.782-798, 2008. ,
DOI : 10.1038/sj.leu.2403491
An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL, Science, vol.277, issue.5327, pp.815-818, 1997. ,
DOI : 10.1126/science.277.5327.815
Use of Mouse Models to Study the Role of Tissue Factor in Tumor Biology, Seminars in Thrombosis and Hemostasis, vol.34, issue.02, pp.182-186, 2008. ,
DOI : 10.1055/s-2008-1079258
Platelet Granule Secretion Continuously Prevents Intratumor Hemorrhage, Cancer Research, vol.68, issue.16, pp.6851-6858, 2008. ,
DOI : 10.1158/0008-5472.CAN-08-0718
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547489
Acquired factor VIII inhibitors in oncohematology: A systematic review, Critical Reviews in Oncology/Hematology, vol.66, issue.3, pp.194-199, 2008. ,
DOI : 10.1016/j.critrevonc.2007.12.004
Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors, Blood, vol.112, issue.4, pp.1151-1153, 2008. ,
DOI : 10.1182/blood-2008-01-132639